Predictors for Response to Dose-dense Docetaxel and Epirubicin Breast Cancer
Condition(s):Stage III Breast Cancer AJCC V7Last Updated:June 29, 2022Active, not recruiting
Hide Studies Not Open or Pending
Condition(s):Stage III Breast Cancer AJCC V7Last Updated:June 29, 2022Active, not recruiting
Condition(s):Stage III Breast Cancer (T0N2, T1N2, T2N2, T3N1, 2 or T4); Stage IIb Breast Cancer (T3N0)Last Updated:January 19, 2024Completed
Condition(s):Breast CancerLast Updated:September 25, 2012Completed
Condition(s):Breast CancerLast Updated:August 2, 2013Suspended
Condition(s):Breast CancerLast Updated:June 6, 2012Completed
Condition(s):Breast Cancer; Breast NeoplasmsLast Updated:March 4, 2008Completed
Condition(s):Male Breast Carcinoma; Stage IIA Breast Cancer AJCC v6 and v7; Stage IIB Breast Cancer AJCC v6 and v7; Stage IIIA Breast Cancer AJCC v7; Stage IIIB Breast Cancer AJCC v7; Stage IIIC Breast Cancer AJCC v7Last Updated:February 6, 2024Active, not recruiting
Condition(s):Breast CancerLast Updated:October 29, 2010Unknown status
Condition(s):Breast CancerLast Updated:October 26, 2015Completed
Condition(s):Stage III Breast CancerLast Updated:August 9, 2019Unknown status
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.